These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy. Bożek A, Kołodziejczyk K. Hum Vaccin Immunother; 2018 Feb 01; 14(2):288-291. PubMed ID: 29106324 [Abstract] [Full Text] [Related]
8. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Gorska L, Chelminska M, Kuziemski K, Skrzypski M, Niedoszytko M, Damps-Konstanska I, Szymanowska A, Siemińska A, Wajda B, Drozdowska A, Jutel M, Jassem E. Int Arch Allergy Immunol; 2008 Feb 01; 147(3):241-5. PubMed ID: 18594155 [Abstract] [Full Text] [Related]
9. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Wenzel J, Meissner-Kraemer M, Bauer R, Bieber T, Gerdsen R. Allergy; 2003 Nov 01; 58(11):1176-9. PubMed ID: 14616130 [Abstract] [Full Text] [Related]
10. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Goldberg A, Yogev A, Confino-Cohen R. Int Arch Allergy Immunol; 2011 Nov 01; 156(1):90-8. PubMed ID: 21447964 [Abstract] [Full Text] [Related]
12. Rush Venom Immunotherapy in Children. Confino-Cohen R, Rosman Y, Goldberg A. J Allergy Clin Immunol Pract; 2017 Nov 01; 5(3):799-803. PubMed ID: 27914814 [Abstract] [Full Text] [Related]
13. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Seitz MJ, Aberer W, Bodzenta-Lukaszyk A, Bonifazi F, Campi P, Darsow U, Haeberli G, Hawranek T, Küchenhoff H, Lang R, Quercia O, Reider N, Schmid-Grendelmeier P, Severino M, Sturm GJ, Treudler R, Wüthrich B. PLoS One; 2013 Nov 01; 8(5):e63233. PubMed ID: 23700415 [Abstract] [Full Text] [Related]
15. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population. Roesch A, Boerzsoenyi J, Babilas P, Landthaler M, Szeimies RM. J Dtsch Dermatol Ges; 2008 Apr 01; 6(4):292-7. PubMed ID: 18042250 [Abstract] [Full Text] [Related]
16. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Birnbaum J, Ramadour M, Magnan A, Vervloet D. Clin Exp Allergy; 2003 Jan 01; 33(1):58-64. PubMed ID: 12534550 [Abstract] [Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase. Stoevesandt J, Hain J, Stolze I, Kerstan A, Trautmann A. Clin Exp Allergy; 2014 Jan 01; 44(5):747-55. PubMed ID: 24447144 [Abstract] [Full Text] [Related]
18. Modified rush venom immunotherapy in dogs with Hymenoptera hypersensitivity. Moore A, Burrows AK, Rosenkrantz WS, Ghubash RM, Hosgood G. Vet Dermatol; 2023 Dec 01; 34(6):532-542. PubMed ID: 37395162 [Abstract] [Full Text] [Related]